This report was first published by Endpoints News. To see the original version, click here
Madrigal Pharmaceuticals is on a mission to become a generational, independent player in the MASH field with its third deal in eight months.
The first FDA-approved medicine for the fatty liver disease, Rezdiffra, has now been on the market for 22 months. And the Pennsylvania biotech is rapidly expanding its pipeline with next-generation candidates.
您已阅读10%（439字），剩余90%（4089字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。